First Patient Dosed in Phase II Clinical Trial of TLL018-205 for PsO

January 20, 2023

TLL-018 is a novel, highly potent, and selective TYK2/JAK1 inhibitor.

The first patient has been enrolled and dosed in a Phase II study evaluating the efficacy and safety of TLL-018 fpr moderate to severe plaque psoriasis.

 This study is sponsored by Hangzhou Highlightll Pharmaceutical Co., Ltd (Highlightll Pharmaceutical, USA).

TLL-018 is a novel, highly potent, and selective TYK2/JAK1 inhibitor. TYK2 and JAK1 are the key regulators of pro-inflammatory cytokines. 

"We are elated to have enrolled our first patient in the TLL018-205 trial. This is a significant milestone for the trial and a noteworthy achievement for our clinical operations team. The investigators on this trial are exceptional and have done a remarkable job pre-screening and using modern patient recruitment tactics," says Joshua Ondatje, VP of Clinical Operations at Vial, in a news release. Vial is a CRO providing next-generation clinical trial management services. 

"We are pleased to hear that Vial has enrolled the first patient for the study. We hope that with the help of Vial's tech-enabled clinical management services, we can complete this trial expeditiously and with high quality," adds Vance Oertel, VP of Clinical Operations at Highlightll Pharmaceutical, USA.

Facebook Comments


We’re glad to see you’re enjoying PracticalDermatology…
but how about a more personalized experience?

Register for free